U.S. markets close in 2 hours 16 minutes
  • S&P 500

    4,275.96
    -29.24 (-0.68%)
     
  • Dow 30

    33,992.74
    -159.27 (-0.47%)
     
  • Nasdaq

    12,943.40
    -159.15 (-1.21%)
     
  • Russell 2000

    1,987.51
    -33.02 (-1.63%)
     
  • Crude Oil

    88.12
    +1.59 (+1.84%)
     
  • Gold

    1,776.70
    -13.00 (-0.73%)
     
  • Silver

    19.74
    -0.35 (-1.74%)
     
  • EUR/USD

    1.0171
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    2.9040
    +0.0800 (+2.83%)
     
  • GBP/USD

    1.2044
    -0.0050 (-0.41%)
     
  • USD/JPY

    135.4710
    +1.2560 (+0.94%)
     
  • BTC-USD

    23,418.65
    -446.63 (-1.87%)
     
  • CMC Crypto 200

    556.52
    -16.29 (-2.84%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Global Genome Engineering Market to Surpass US$ 15,195.74 Million by 2030 - Coherent Market Insights

·5 min read

SEATTLE, July 15, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global genome engineering market is estimated to be valued at US$ 5,205.60 million in 2022 and is expected to exhibit a CAGR of 14.3% during the forecast period (2022-2030).

Coherent_Market_Insights_Logo
Coherent_Market_Insights_Logo

Key Trends and Analysis of the Global Genome Engineering Market:

Strategic collaboration of key players in market for genome engineering technologies is also expected to positively affect market growth. For instance, January 2018, two key players, Sangamo Therapeutics Inc. and Pfizer Inc. entered into a strategic collaboration for development of potential gene therapy using zinc finger protein transcription factors (ZFP-TFs), to treat amyotrophic lateral sclerosis (ALS).

Market Dynamics

Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth over the forecast period. Key players in market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. would use Sangamo Therapeutics' zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide ribonucleic acid (RNA) products for CRISPR genome engineering.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1262

Key Market Takeaways:

Global genome engineering market is expected to exhibit a CAGR of 14.3% during the forecast period due to increasing research and development genome engineering technology. For instance, in February 2022, according to data published by National Center for Biotechnology Information, using gene editing technologies, the sequence in the human genome can be precisely engineered to achieve a therapeutic effect.  The ability to make site-specific modifications to the human genome, has invoked a paradigm shift in gene therapy by use of ZFN-mediated gene editing for human gene therapy.

Among technologies, the CRISPR segment is expected to dominate the segment growth over the forecast period, owing to increased research and development activities for advancing genome engineering by key players in market. For instance, in October 2019, in a new study published in Proceedings of the National Academy of Sciences (PNAS), scientists present a new addition to the promising CRISPR toolkit called CRISPR-BEST. This tool operates with an efficient method to create mutations in actinomycetes without requiring a Deoxyribonucleic Acid (DNA) double-stranded break. Although CRISPR-Cas9 tools dramatically simplified the genetic manipulation of actinomycetes, significant concerns of genome instability caused by the DNA double-strand breaks (DSBs) and common off-target effects remained. To address these concerns, CRISPR-BEST was developed, a DSB-free and high-fidelity single-nucleotide–resolution base editing system for Streptomyces.

Key players operating in the global genome engineering market include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1262

Detailed Segmentation:

Global Genome Engineering Market, By Technology:

  • CRISPR

  • TALEN

  • ZFN

  • Others

Global Genome Engineering Market, By Application:

  • Cell Line Engineering

  • Genetic Engineering

Global Genome Engineering Market, By End User:

  • Biotechnology & Pharmaceutical Companies

  • Research Institutes

  • Contract Research Organization

Global Genome Engineering Market, By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/1262

Find more related trending reports below:

Digital Genome Market, by Product Type (Sequencer & Analyzers, Reagents & Kits and Sequencing & Analysis Software), by Application (Clinical (Reproductive Health, Oncology, and Others), Forensics, Drug Discovery and Development and Other Applications), by End User (Hospitals, Diagnostic Centers, Research Institutes, Biotechnology and Pharmaceutical Companies and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Single Cell Genome Sequencing Market, by Product (Kits and Reagents and Instruments), by Technology (Next Generation Sequencing, PCR, qPCR, Microarray, MDA, and Others), by End User (Research and Academic Institutes, Sequencing laboratories, Pharmaceutical and Biotech Companies, and Others), and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Artificial Intelligence in Digital Genome Market, by Offering (Software and Services), by Technology (Machine Learning and Computer Vision), by Functionality (Genome Sequencing and Gene Editing), by Application (Diagnostics, Drug Discovery & Development, Precision Medicine, Agriculture & Animal Research, and Other Applications), by End User (Pharmaceutical & Biotech Companies and Research Bodies), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedInTwitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/global-genome-engineering-market-to-surpass-us-15-195-74-million-by-2030--coherent-market-insights-301587331.html

SOURCE Coherent Market Insights